Consensus Exelixis, Inc.

Stocks

EXEL

US30161Q1040

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2026-10-30 pm EDT			5-day change	1st Jan Change
69.39 ^USD	+4.82%		+7.53%	+58.32%

Oct. 30	RBC Raises Price Target on Exelixis to $58 From $51, Keeps Sector Perform Rating	MT
Oct. 30	Analyst recommendations: GE Vernova, Intel, Reddit, Caterpillar, Crocs…

Evolution of the Average Target: Exelixis, Inc.

Evolution of the Target Price: Exelixis, Inc.

Changes in Analyst Recommendations: Exelixis, Inc.

d4b6e0bb67878.7JPiFhhTsVXnddYynH48LJpvvp9mOLbLEomQifvuMnw.uuqhdUpg1j_WQp14zSleYukD5u0Ba-Wta-zXpJ-DBhqi99N_WTf3Mo0Ahw~108bfe8f1ebf8e36677173fda64fea16

Analysts' recommendations: Exelixis, Inc.

Oct. 30	RBC Raises Price Target on Exelixis to $58 From $51, Keeps Sector Perform Rating	MT
Oct. 30	Analyst recommendations: GE Vernova, Intel, Reddit, Caterpillar, Crocs…
Oct. 09	Exelixis' Zanzalintinib Clinical Trials for Cancer Highly Likely to Succeed, RBC Says	MT
Oct. 09	RBC Raises Price Target on Exelixis to $51 From $45, Keeps Sector Perform Rating	MT
Oct. 08	RBC Trims Price Target on Exelixis to $45 From $46, Keeps Sector Perform Rating	MT
Jul. 23	Analyst recommendations: Duke Energy, JPMorgan Chase, M&T Bank, Super Micro, Texas Instruments…
Jul. 13	Analyst recommendations: Biogen, Deckers Outdoor, Fortinet, Marathon Petroleum, UnitedHealth…
Jul. 07	RBC Capital Adjusts Exelixis Price Target to $46 From $43, Maintains Sector Perform Rating	MT
Jul. 02	Exelixis Faces Balanced Risk-Reward Ahead of Key Catalysts, UBS Says	MT
Jul. 02	UBS Adjusts Price Target on Exelixis to $52 From $43, Maintains Neutral Rating	MT
Jul. 02	Analyst recommendations: Adobe, AA, Nike, Exelixis…
May. 06	Exelixis Seen Trading Steady on Modest Drug Growth, RBC Says	MT
Mar. 02	RBC Lowers Price Target on Exelixis to $43 From $46, Keeps Sector Perform Rating	MT
Feb. 11	RBC Raises Price Target on Exelixis to $46 From $45, Keeps Sector Perform Rating	MT
Feb. 02	Morgan Stanley Lifts Price Target on Exelixis to $49 From $48, Keeps Overweight Rating	MT
Jan. 14	Truist Securities Adjusts Price Target on Exelixis to $51 From $49, Maintains Buy Rating	MT
Jan. 08	Exelixis Shares Fall After Downgrade From Morgan Stanley	MT
Jan. 08	Morgan Stanley Downgrades Exelixis to Equalweight, Price Target is $48	MT
Jan. 05	Exelixis Faces Limited High-Impact Catalysts, BofA Says	MT
Jan. 05	BofA Securities Downgrades Exelixis to Underperform From Neutral, Adjusts Price Target to $41 From $43	MT
Nov. 06	UBS Adjusts Price Target on Exelixis to $40 From $35, Maintains Neutral Rating	MT
Nov. 05	Morgan Stanley Lifts Price Target on Exelixis to $45 From $44, Keeps Overweight Rating	MT
Nov. 03	Exelixis Shares Fall After Guggenheim Downgrade	MT
Nov. 03	Guggenheim Downgrades Exelixis to Neutral From Buy	MT
25-10-21	Exelixis Shares Rise After Leerink Partners Upgrade	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	EXELIXIS, INC.					-13.84%
	WUXI APPTEC CO., LTD.					+42.48%
	ARGENX SE					+24.46%
	LONZA GROUP AG					+8.88%
	IQVIA HOLDINGS INC.					+15.87%
	BEONE MEDICINES AG					+17.86%
	REVOLUTION MEDICINES, INC.					+35.3%
	GENMAB A/S					+1.94%
	CELLTRION, INC.					+41.27%
	INSMED INCORPORATED					+72.28%
	Average					+24.65%
	Weighted average by Cap.					+25.39%